Publication:
Growth hormone therapy update in Thailand

Simple item page
dc.contributor.authorKitti A. Angsusinghaen_US
dc.contributor.authorSuttipong Watcharasindhuen_US
dc.contributor.authorSupawadee Likitmaskulen_US
dc.contributor.authorChanika Tuchindaen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-07-04T08:03:52Z
dc.date.available2018-07-04T08:03:52Z
dc.date.issued1998-03-01en_US
dc.description.abstractThere were 841 children in Thailand with growth hormone deficiency (GHD) from January 1992 to 1996. Idiopathic isolated GHD was the major diagnosis. Only 40.19% received recombinant DNA human growth hormone (rhGH) treatment. Also reported here is a 1-2 year study of rhGH therapy in 30 GH-deficient children (21 males, 9 females), aged (mean ± SD) 10.41 ± 3.16 years, and bone age 7.37 ± 3.34 years. The height velocity 1 and 2 years post-treatment were 8.17 ± 1.9 and 7.36 ± 2.8 cm/year respectively, which were statistically significant compared to pretreatment values of 3.91 ± 1.09 cm/year. Improved height SDS was observed at the end of each treatment period. Thyroid function and glycosylated hemoglobin tests were normal during the treatment period. There were no reports of side effects.en_US
dc.identifier.citationHormone Research. Vol.49, No.SUPPL. 1 (1998), 15-20en_US
dc.identifier.doi10.1159/000053063en_US
dc.identifier.issn03010163en_US
dc.identifier.other2-s2.0-0031934014en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/18309
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0031934014&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleGrowth hormone therapy update in Thailanden_US
dc.typeConference Paperen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0031934014&origin=inwarden_US

Files

Collections

Scopus 1991-2000